Approved for use within the UK in 2022, TruCheck is allowing people to go beyond what’s currently possible with cancer screening. With a single blood test, TruCheck can detect signals from 70 types of cancer.
The TruCheck test underwent rigorous evaluation in clinical studies involving more than 40,000 participants. Developed by Datar Cancer Genetics, its clinical laboratory boasts certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), as well as accreditation by the College of American Pathologists (CAP).
CancerScan UK Ltd is at the forefront of early cancer detection, utilising the TruCheck system to identify multiple types of cancer at their earliest stages. The technology and services can provide immense value for life insurance companies seeking to manage risk, enhance client satisfaction, and contribute to the health and well-being of policyholders.
Here’s what our partnership could offer you:
Partnering with CancerScan UK Ltd not only helps protect your business interests, but it also demonstrates an investment in the health of your clients. To discuss how our services can benefit your company, please contact us at lifeinsurrance@cancerscanuk.co.uk. We look forward to the opportunity to collaborate for healthier futures.
Please fill in the following form and we’ll get back to you. Our typical response time is 2 hours. You can also contact us at +44 20 8133 4424 or help@cancerscanuk.co.uk
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
